= 0.002). These findings identify S100P as a prognostic biomarker for dCCA, suggesting its clinical utility for postoperative risk stratification and patient management.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: